Linked Life Data

18474002

Source:http://linkedlifedata.com/resource/pubmed/id/18474002

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2008-5-13
pubmed:abstractText
Three U.S. National Cancer Institute cooperative group randomized phase 3 trials have demonstrated that the intraperitoneal delivery of cisplatin-based chemotherapy as primary treatment of small-volume residual advanced ovarian cancer improves survival compared to the administration of all agents by the intravenous route. As use of intraperitoneal chemotherapy requires additional resources and expertise beyond that associated with routine intravenous treatment, and unique side effects may be observed (e.g., catheter malfunction, intra-abdominal infection), some have questioned the utility of this approach, despite the documented survival advantage. This review outlines the data supporting intraperitoneal delivery in ovarian cancer, discusses strategies to safely and effectively employ regional therapy, and highlights areas where future trials are required to optimize this novel method for treatment of this malignancy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1574-8871
pubmed:author
pubmed:issnType
Print
pubmed:volume
2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
169-73
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Intraperitoneal chemotherapy as primary treatment of advanced ovarian cancer: efficacy, toxicity, and future directions.
pubmed:affiliation
Department of Gynecologic Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. mmarkman@mdanderson.org
pubmed:publicationType
Journal Article, Comparative Study, Review